LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Elenco Azioni・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

21.12 -0.94

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

20.97

Massimo

21.5

Metriche Chiave
By Trading Economics
Entrata	-270M 3.6M
Vendite	-16M 268M
P/E Media del settore	9.362 49.701
EPS	0.02
Margine di Profitto	1.357
Dipendenti	796
EBITDA	-31M -4.6M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+53.71% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-256M 3.5B
Apertura precedente	22.06
Chiusura precedente	21.12

Notizie sul Sentiment di mercato

By Acuity

50%

148 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

14.845 / N/A Supporto e resistenza

ACADIA Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 mag 2026, 22:48 UTC

Acquisizioni, Fusioni, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 mag 2026, 16:49 UTC

Utili

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 mag 2026, 16:26 UTC

I principali Market Mover

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 mag 2026, 23:51 UTC

Discorsi di Mercato

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 mag 2026, 23:37 UTC

Utili

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 mag 2026, 23:37 UTC

Utili

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 mag 2026, 23:37 UTC

Utili

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 mag 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 mag 2026, 23:30 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

21 mag 2026, 23:30 UTC

Discorsi di Mercato

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 mag 2026, 22:33 UTC

Acquisizioni, Fusioni, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164M

21 mag 2026, 21:53 UTC

Utili

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 mag 2026, 21:02 UTC

Utili

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 mag 2026, 20:55 UTC

Utili

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 mag 2026, 20:30 UTC

Azioni calde

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 mag 2026, 20:20 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

21 mag 2026, 20:20 UTC

Discorsi di Mercato

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 mag 2026, 20:20 UTC

Utili

Webull 1Q Adj EPS 3c >BULL

21 mag 2026, 20:20 UTC

Utili

Webull 1Q Rev $159.9M >BULL

21 mag 2026, 20:18 UTC

Discorsi di Mercato

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 mag 2026, 20:18 UTC

Utili

Webull 1Q Loss/Shr 4c

21 mag 2026, 19:43 UTC

Discorsi di Mercato

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 mag 2026, 19:33 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 mag 2026, 18:58 UTC

Utili

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 mag 2026, 18:15 UTC

Discorsi di Mercato

Gold Higher For Second Consecutive Day -- Market Talk

21 mag 2026, 17:40 UTC

Discorsi di Mercato

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 mag 2026, 17:04 UTC

Discorsi di Mercato

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 mag 2026, 17:01 UTC

Utili

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 mag 2026, 16:20 UTC

Discorsi di Mercato

Utili

Stellantis Targets Distant but Constructive -- Market Talk

21 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

ACADIA Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

53.71% in crescita

Previsioni per 12 mesi

Media 32.77 USD 53.71%

Alto 38 USD

Basso 24 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per ACADIA Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

15 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 15 che hanno fornito valutazioni azionarie a ACADIA Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

14.845 / N/ASupporto e resistenza

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

148 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.